Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma
Yıl: 2020 Cilt: 30 Sayı: 2 Sayfa Aralığı: 103 - 109 Metin Dili: İngilizce DOI: 10.4999/uhod.204187 İndeks Tarihi: 19-11-2020
Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma
Öz: The prognosis of melanoma is extremely poor. There are no biomarker that indicate the prognosis. The indirect markers of the antitumoral response such as the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), derived NLR (dNLR), absoluteneutrophil count (ANC), absolute lymphocyte count (ALC) etc. have recently begun to be emphasized. Increased NLR, PLR and dNLRas a consequence of chronic inflammation have been found to be associated with poor prognosis in many cancers. The aim of thisstudy is explore the role of this parameters in patients with early-stage melanoma. We retrospectively evaluated 120 patients admittedto our clinic with stage I-III melanoma with ANC, ALC, absolute platelet count(APC), as well as NLR, dNLR, and PLR values at the timeof diagnosis, relaps and metastasis and evaluate their impact on prognosis. Patients with active infection, receiving steroids, with achronic inflammatory disease that may alter the hematological parameters, and those with another malignancy other than melanomawere excluded. The median follow-up was 52 months. OS and DFS were significantly worse in patients with an NLR above 2.84.Also, in patients with a dNLR value above 1.96 (p= 0.007). The were no relationship between PLR value, OS and DFS, and betweengender and OS. OS was significantly lower in patients over 65 years of age (p< 0.001). These results suggested that haematologicalparameters can be used to estimate the prognosis of melanoma. These results suggested that haematological parameters can beused to estimate the prognosis of melanoma
Anahtar Kelime: Erken Evre Malign Melanom Hastalarında Hematolojik Parametrelerin Prognostik Önemi
Öz: Melanom oldukça kötü prognozlu bir malignitedir, fakat prognozu belirleyebilecek bir biyobelirteç yoktur. Nötrofil / lenfosit oranı (NLR) ve trombosit / lenfosit oranı (PLR), türetilmiş NLR (dNLR), mutlak nötrofil sayısı (ANC), mutlak lenfosit sayısı (ALC) gibi antitümoral yanıtın dolaylı belirteçleri yakın zamanda araştırılmaya başlanmıştır. Kronik inflamasyonun bir sonucu olarak artan NLR, PLR ve dNLR’nin birçok kanserde kötü prognoz ile ilişkili olduğu bulunmuştur. Bu çalışmanın amacı, erken evre melanomalı hastalarda bu parametrelerin rolünü araştırmaktır. Kliniğimize evre I-III melanoma tanısıyla başvuran 120 hastayı ANC, ALC, mutlak trombosit sayımı (APC) ve ayrıca NLR, dNLR ve PLR değerleri ile tanı, relaps ve metastaz sırasında yapılan ölçümler ve bu ölçümlerin sağ kalım üzerine etkilerini değerlendirdik. Hematolojik parametreleri değiştirebilecek kronik enflamatuar bir hastalığı olan, steroid alan, aktif enfeksiyonu olan hastalar ve melanom dışında başka bir malignitesi olan hastalar çalışma dışı bırakıldı. Ortalama takip süresi 52 aydı. OS ve DFS, NLR’nin 2.84 üzerinde olduğu hastalarda ve dNLR değeri 1,96’nın üzerinde olan hastalarda (p= 0.007) anlamlı olarak daha kötüydü. PLR değeri, OS ve DFS ile cinsiyet ve OS arasında ilişki yoktu. OS, 65 yaş üstü hastalarda anlamlı derecede daha kötüydü (p< 0.001). Bu sonuçlar, hematolojik parametrelerin, melanomun prognozunu tahmin etmek için kullanılabileceğini göstermiştir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
- 2. Green AC, Baade P, Coory M, et al. Population-based 20- year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol 30: 1462-1467, 2012.
- 3. Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol 32: 2479-2485, 2014.
- 4. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634, 2001.
- 5. Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 93: 273-278, 2005.
- 6. Margolis KL, Rodabough RJ, Thomson CA, et al. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 167: 1837-1844, 2007.
- 7. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107: 695-699, 2012.
- 8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature 454: 436-444. 2008.
- 9. Schmidt H, Suciu S, Punt CJ, et al. American Joint Committee on Cancer Stage IV Melanoma; EORTC 18951. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 25: 1562-1569, 2007.
- 10. Baykan H, Cihan YB, Ozyurt K. Roles of white blood cells and subtypes as inflammatory markers in skin cancer. Asian Pac J Cancer Prev 16: 2303-2306, 2015.
- 11. Zaragoza J, Caille A, Beneton N, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol 174: 146-151, 2016.
- 12. Di Giacomo AM, Calabrò L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 62: 1021-1028, 2013.
- 13. Ferrucci PF, Gandini S, Battaglia A, et al. Baseline neutrophilto-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 112: 1904-1910, 2015.
- 14. Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22: 5487-5496, 2016.
| APA | Semiz H, Kazaz S, DEMIR N, Güç Z, Yavuzsen T, Ellidokuz H, ÖZTOP İ, SOMALI I (2020). Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. , 103 - 109. 10.4999/uhod.204187 |
| Chicago | Semiz Huseyin Salih,Kazaz Seher Nazlı,DEMIR NECLA,Güç Zeynep Gülsüm,Yavuzsen Tugba,Ellidokuz Hülya,ÖZTOP İLHAN,SOMALI Işıl Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. (2020): 103 - 109. 10.4999/uhod.204187 |
| MLA | Semiz Huseyin Salih,Kazaz Seher Nazlı,DEMIR NECLA,Güç Zeynep Gülsüm,Yavuzsen Tugba,Ellidokuz Hülya,ÖZTOP İLHAN,SOMALI Işıl Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. , 2020, ss.103 - 109. 10.4999/uhod.204187 |
| AMA | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. . 2020; 103 - 109. 10.4999/uhod.204187 |
| Vancouver | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. . 2020; 103 - 109. 10.4999/uhod.204187 |
| IEEE | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I "Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma." , ss.103 - 109, 2020. 10.4999/uhod.204187 |
| ISNAD | Semiz, Huseyin Salih vd. "Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma". (2020), 103-109. https://doi.org/10.4999/uhod.204187 |
| APA | Semiz H, Kazaz S, DEMIR N, Güç Z, Yavuzsen T, Ellidokuz H, ÖZTOP İ, SOMALI I (2020). Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. Uluslararası Hematoloji-Onkoloji Dergisi, 30(2), 103 - 109. 10.4999/uhod.204187 |
| Chicago | Semiz Huseyin Salih,Kazaz Seher Nazlı,DEMIR NECLA,Güç Zeynep Gülsüm,Yavuzsen Tugba,Ellidokuz Hülya,ÖZTOP İLHAN,SOMALI Işıl Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. Uluslararası Hematoloji-Onkoloji Dergisi 30, no.2 (2020): 103 - 109. 10.4999/uhod.204187 |
| MLA | Semiz Huseyin Salih,Kazaz Seher Nazlı,DEMIR NECLA,Güç Zeynep Gülsüm,Yavuzsen Tugba,Ellidokuz Hülya,ÖZTOP İLHAN,SOMALI Işıl Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. Uluslararası Hematoloji-Onkoloji Dergisi, vol.30, no.2, 2020, ss.103 - 109. 10.4999/uhod.204187 |
| AMA | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(2): 103 - 109. 10.4999/uhod.204187 |
| Vancouver | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma. Uluslararası Hematoloji-Onkoloji Dergisi. 2020; 30(2): 103 - 109. 10.4999/uhod.204187 |
| IEEE | Semiz H,Kazaz S,DEMIR N,Güç Z,Yavuzsen T,Ellidokuz H,ÖZTOP İ,SOMALI I "Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma." Uluslararası Hematoloji-Onkoloji Dergisi, 30, ss.103 - 109, 2020. 10.4999/uhod.204187 |
| ISNAD | Semiz, Huseyin Salih vd. "Prognostic Significance of Hematological Parameters in Patients with Early-Stage Malignant Melanoma". Uluslararası Hematoloji-Onkoloji Dergisi 30/2 (2020), 103-109. https://doi.org/10.4999/uhod.204187 |
